Seòmar agus comataidhean

The appearance of synthetic opioids in the drug supply has been a concern for Scottish Government for some time and something which will likely be exacerbated by the reduction in opium production as reported by the UNODC. We are working alongside colleagues across the UK to identify areas for collaborative working on this issue with the various UK administrations, national police forces and the National Crime Agency.

Synthetic opioids, such as fentanyl, are often extremely potent opioid receptor agonists, however, naloxone is still effective in the treatment of any overdose. This is why we have invested over £3 million in widening access to naloxone, making it easier for people to access and supporting Police Scotland and our other emergency services to carry kits.

Having reliable data about substances of concern in the drug supply is key and is why we have supported Public Health Scotland to establish the RADAR (Rapid Action Drug Alerts and Response) system. We also continue to progress plans with local partners to establish drug checking facilities as this will also provide up-to-date information about the substances in the drug supply. We are aware that nitazenes have been present in the drug supply and Public Health Scotland issued an alert regarding nitazenes in January 2023 and the UK Government have since issued a similar alert. RADARs quarterly report published in October 2023 also reported that nitzenes have been detected in post-mortem and hospital toxicology samples.

Recognising the global challenge around the appearance of new synthetic opioids, the Minister for Drug and Alcohol Policy and members of the Scottish Governments National Mission Oversight Group on Drugs are meeting with international colleagues to hear about their experience of dealing with the appearance of fentanyl and synthetic opioids in the drug supply, and their response, in early November. A further meeting is being organised to discuss operational level issues with international colleagues and Scottish drug service delivery providers.

This year’s COVID-19 vaccine marketing and communication plan utilises a number of communication channels to reach those with a weakened immune system, under the “Don’t let your protection fade” campaign. The accompanying marketing toolkit includes a range of assets directed at those who are at higher risk of COVID-19. This toolkit has been shared with Health Boards and stakeholders for them to promote via their own communication channels. The national campaign has also promoted vaccination for those at clinical risk.

All those eligible for winter vaccination have been sent an invitation letter with either a scheduled appointment or instructions on how to book an appointment. Included with this is a leaflet which includes information around why those eligible are being offered a COVID-19 vaccine this winter.

Specific leaflets have been produced for the clinical at risk child and infant groups. These leaflets are designed to help parents/carers make an informed decision about getting their child vaccinated.

All programme patient leaflets can be viewed on NHS Inform.

Winter vaccines briefings for professionals working with people at higher risk are available on the Public Health Scotland website. These explain the importance of the winter vaccines and encourage healthcare professionals to speak to their patients about being vaccinated.

The Endometriosis Referral Care Pathway for Scotland was published by the Centre for Sustainable Delivery in January 2023 and distributed to NHS Scotland Boards.

We will continue to work with the Centre for Sustainable Delivery to support implementation of the pathway through the National Gynaecology Specialty Delivery Group.

We are jointly funding a £250,000 endometriosis research project with the charity Wellbeing of Women. The research project, which will primarily be run by researchers at The University of Edinburgh, will look at the drug dichloroacetate in the management of endometriosis-associated pain.

Additionally, in January 2023 our Chief Scientist Office announced funding for the ENDOCAN project, led by researchers at The University of Edinburgh. Through a large scale UK-wide trial, the research will investigate whether a cannabinoid can reduce endometriosis-associated pain. Funding of £299,509 has been committed to this 30 month project.

The Chief Scientist Office also invited applications to the Applied Health Research Programmes Funding in March this year. Applicants will be informed of the outcome in December 2023.

Public Health Scotland (PHS) publishes incidence and mortality data on leukaemias, Hodgkin lymphoma, Non-Hodgkin lymphoma and multiple myeloma annually.

PHS previously published survival data on these same cancers. However in the 2023 release, a different approach was taken to assess the short-term impact of COVID-19 on cancer survival for a select few cancers. It utilised a much smaller cohort than the usual methodology which meant an estimate of survival for rarer cancers could not be calculated. Some estimates for blood cancers are available for the 2016-2020 cohort upon request to PHS.

In future cancer survival publications, these same blood cancers will be included again, as survival publications will revert back to previous methodology.

The Scottish Government currently has no plans to introduce such a register. We are working with Local Authorities, Health Boards and other public sector partners to understand the extent to which RAAC is present in buildings and any actions necessary in response.

This is a matter for NHS National Services Scotland National Services Division. The information requested is not held centrally.

The detailed information requested is currently being collated and once it is available it will be placed in the Scottish Parliament Information centre under Bib. Number 64646.

I refer the member to the answer to question S6W-22759 on 14 November 2023. All answers to written parliamentary questions are available on the Parliament’s website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers

I refer the member to the answer to question S6W-22760 on 14 November 2023. All answers to written parliamentary questions are available on the Parliament’s website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers